Literature DB >> 429140

Efficient ribosome binding of brome mosaic virus (BMV) RNA4 contributes to its ability to outcompete the other BMV RNAs for translation.

J W Pyne, T C Hall.   

Abstract

Analysis of translation products synthesized in vitro in the presence of a mixture of brome mosaic virus (BMV) RNAs 1, 2, 3, and 4 usually shows a predominance of coat protein, coded by RNA4. The proportion of products directed by RNAs 1 and 2 decreased at saturating concentrations of BMV RNA and in the presence of 7-methylguanosine 5'-phosphate (m7G5'p) at nonsaturating concentrations of RNA. No differences in the relative proportions of the various proteins produced were detected in the presence of T-2 toxin, which interferes with the formation of the first peptidyl bond rather than competing for initiation factor, as has been suggested for m7G5'p. These data show that the ability of BMV RNA4 to outcompete BMV RNAs 1, 2, and 3 results, at least in part, from its ability to bind more efficiently to ribosomes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429140     DOI: 10.1159/000149008

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  4 in total

Review 1.  Translational control in positive strand RNA plant viruses.

Authors:  Theo W Dreher; W Allen Miller
Journal:  Virology       Date:  2006-01-05       Impact factor: 3.616

2.  trans regulation of cap-independent translation by a viral subgenomic RNA.

Authors:  Ruizhong Shen; Aurélie M Rakotondrafara; W Allen Miller
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Requirement for a viral trans-acting factor encoded by brome mosaic virus RNA-2 provides strong selection in vivo for functional recombinants.

Authors:  A L Rao; T C Hall
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  In vitro quantification of the relative packaging efficiencies of single-stranded RNA molecules by viral capsid protein.

Authors:  Mauricio Comas-Garcia; Ruben D Cadena-Nava; A L N Rao; Charles M Knobler; William M Gelbart
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.